Randomised trial of azithromycin to eradicate Ureaplasma in preterm infants. Issue 6 (13th March 2020)

• Record Type: Journal Article
• Authors: Viscardi, Rose Marie; Terrin, Michael L; Magder, Laurence S; Davis, Natalie L; Dulkerian, Susan J; Waites, Ken B; Ambalavanan, Namasivayam; Kaufman, David A; Donohue, Pamela; Tuttle, Deborah J; Weitkamp, Jorn-Hendrik; Hassan, Hazem E; Eddington, Natalie D
• Is Part Of: Archives of disease in childhood. Volume 105:Issue 6(2020)
• Page Start: 615
• Page End: 622
• Publication Date: 2020-03-13
• Subjects: neonatology -- ureaplasma parvum -- ureaplasma urealyticum -- prematurity -- bronchopulmonary dysplasia; Infants -- Diseases -- Periodicals; Newborn infants -- Diseases -- Periodicals; Fetus -- Diseases -- Periodicals; 618.920105
• DOI: 10.1136/archdischild-2019-318122
• Languages: English
• ISSNs: 1359-2998

Abstract

Abstract : Objective: To test whether azithromycin eradicates Ureaplasma from the respiratory tract in preterm infants. Design: Prospective, phase IIb randomised, double-blind, placebo-controlled trial. Setting: Seven level III–IV US, academic, neonatal intensive care units (NICUs). Patients: Infants 24 0 –28 6 weeks' gestation (stratified 24 0 –26 6 ; 27 0 –28 6 weeks) randomly assigned within 4 days following birth from July 2013 to August 2016. Interventions: Intravenous azithromycin 20 mg/kg or an equal volume of D5W (placebo) every 24 hours for 3 days. Main outcome measures: The primary efficacy outcome was Ureaplasma -free survival. Secondary outcomes were all-cause mortality, Ureaplasma clearance, physiological bronchopulmonary dysplasia (BPD) at 36 weeks' postmenstrual age, comorbidities of prematurity and duration of respiratory support. Results: One hundred and twenty-one randomised participants (azithromycin: n=60; placebo: n=61) were included in the intent-to-treat analysis (mean gestational age 26.2±1.4 weeks). Forty-four of 121 participants (36%) were Ureaplasma positive (azithromycin: n=19; placebo: n=25). Ureaplasma -free survival was 55/60 (92% (95% CI 82% to 97%)) for azithromycin compared with 37/61 (61% (95% CI 48% to 73%)) for placebo. Mortality was similar comparing the two treatment groups (5/60 (8%) vs 6/61 (10%)). Azithromycin effectively eradicated Ureaplasma in all azithromycin-assigned colonised infants, but 21/25 (84%) Ureaplasma -colonised participants receiving placebo were culture positive at one or more follow-up timepoints. Most of the neonatal mortality and morbidity was concentrated in 21 infants with lower respiratory tract Ureaplasma colonisation. In a subgroup analysis, physiological BPD-free survival was 5/10 (50%) (95% CI 19% to 81%) among azithromycin-assigned infants with lower respiratory tract Ureaplasma colonisation versus 2/11 (18%) (95% CI 2% to 52%) in placebo-treated infants. Conclusion: A 3-day azithromycin regimen effectively eradicated respiratory tract Ureaplasma colonisation in this study. Trial registration number: NCT01778634 .